http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

N+1 Singer needs to update this share. They are slow sometimes. :-))

Buying at 12p :-))

A 2 bagger for me and still looking up.

SUMMIT PRESENTS NEW PRECLINICAL AND CLINICAL DATA ON SELECTIVE C. DIFFICILE ANTIBIOTIC SMT19969 AT ICAAC 2013

:-))

Summit presentations points to antibiotic's potential
By Ian Lyall September 11 2013, 7:33am The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Drug developer Summit (LON:SUMM) is presenting data that points to the huge potential of its antibiotic in tackling the C.difficile superbug.

The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Delegates will be told that the company’s phase-one clinical trial of 56 healthy volunteers revealed the drug to be well tolerated in all doses and sparing on gut flora.

The major bacteria groups were largely unchanged with the exception of total Clostridia, which were reduced during treatment.

Results from preclinical efficacy studies were similarly encouraging.

Evaluating the potency and selectivity of SMT19969, they reveal it is highly targeted, but kills all strains of C.diff tested.

A separate analysis of SMT19969 reveals its use with traditional antibiotics does not diminish its potency.

The data will be revealed in five posters and podium presentation at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (IAAC) meeting in Denver.

Summit chief executive Glyn Edwards said: "These new data presented at ICAAC 2013 further validates the promise of SMT19969 as a novel and highly targeted antibiotic for the treatment of this serious infectious disease.

"These results demonstrate that SMT19969 selectively kills all C.difficile strains tested, is highly sparing of healthy gut flora and shows no reduction in activity when used in combination with other antibiotics. This profile is encouraging for treating CDI and significantly reducing rates of recurrent disease and we look forward to advancing SMT19969 into phase-two clinical trials in the second half of 2014."

Come on N+1 Singer upgrades needed fast.

Come on N+1 Singer upgrades needed fast.

Just taken some more off of the table here @13.61

Closed up 17.71%

You lucky guys - I never joined unfortunately although I have looked at them for years. Well done.

:-))

Another good day.

Doing well and I did not join, should have got in weeks ago but hey ho. Well done to all that did.

Profit taking today, with the usual 10% fall after a good rise.

Target price in the short term 22p
http://onlinebusinessuniversity.blogspot.co.uk/2013/09/summit-corporation-period-of-excellent.html#chitika_close_button

I haven't been this excited by a share since Staneco and edible packaging and PDX and their Pump with no moving parts. Both of these rocketed whilst I was on board and later collasped but I was long gone...Can SUMM make it where these two failed and actually make money for the company and shareholders over the long term?
In at 4p 4.87p and 14p
Di
:-)

Posted a week ago on ll - The last target set by this guy was broken for this reason. Charts don't work with news driven stock.

The reality is that Summit's peers in the USA are valued at what would equate to 85p or higher for Summit, this is the reason for the rise, particularly as Summit is now presenting it's finding to a US audience who tend to appreciate the work of BioTechs unlike in the UK.

I expect this stock to keep rising, and if anyone of it's lead drugs makes it to the market place, then it will be £2 per share, not 85-100p and certainly way above some chartists 20p! 12p made me laugh, so does 20p!

IMHO, DYOR etc

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII


September 20, 2013 | By John Carroll




http://www.fiercebiotech.com/story/muscular-dystrophy-drug-glaxosmithkline-prosensa-fails-phiii/2013-09-20

Sad for the families, may prove very good for Summit investors. Still a way to go yet.